NASDAQ:CPIX Cumberland Pharmaceuticals (CPIX) Stock Price, News & Analysis $4.87 +0.10 (+2.10%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cumberland Pharmaceuticals Stock (NASDAQ:CPIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CPIX alerts:Sign Up Key Stats Today's Range$4.84▼$4.9750-Day Range$3.91▼$6.7752-Week Range$1.04▼$7.25Volume4,569 shsAverage Volume1.25 million shsMarket Capitalization$68.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Read More… Cumberland Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreCPIX MarketRank™: Cumberland Pharmaceuticals scored higher than 17% of companies evaluated by MarketBeat, and ranked 850th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cumberland Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cumberland Pharmaceuticals is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cumberland Pharmaceuticals is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCumberland Pharmaceuticals has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cumberland Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.82% of the float of Cumberland Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCumberland Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cumberland Pharmaceuticals has recently decreased by 37.43%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCumberland Pharmaceuticals does not currently pay a dividend.Dividend GrowthCumberland Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.82% of the float of Cumberland Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCumberland Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cumberland Pharmaceuticals has recently decreased by 37.43%, indicating that investor sentiment is improving significantly. News and Social Media1.3 / 5News Sentiment0.41 News SentimentCumberland Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cumberland Pharmaceuticals this week, compared to 10 articles on an average week.Search InterestOnly 1 people have searched for CPIX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cumberland Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders44.85% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.51% of the stock of Cumberland Pharmaceuticals is held by institutions.Read more about Cumberland Pharmaceuticals' insider trading history. Receive CPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPIX Stock News HeadlinesCara Therapeutics (NASDAQ:CARA) and Cumberland Pharmaceuticals (NASDAQ:CPIX) Critical AnalysisApril 22, 2025 | americanbankingnews.comFIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific ConferenceMarch 19, 2025 | prnewswire.comThe 5 Stocks to Buy for Maximum Gains During Trump's PresidencyNew Presidency. New Policy. New Profit Potential. Trump’s return brings fresh momentum to specific sectors. This free report outlines five stocks poised to outperform in a shifting political and economic landscape.April 29, 2025 | Darwin (Ad)What $400,000 can buy you in Cumberland County, March 3 to 9March 13, 2025 | nj.comCumberland Pharmaceuticals Full Year 2024 Earnings: US$0.46 loss per share (vs US$0.44 loss in FY 2023)March 13, 2025 | finance.yahoo.comCumberland Pharmaceuticals: Key Insights from Earnings CallMarch 5, 2025 | tipranks.comCumberland Pharmaceuticals Inc.: Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue GrowthMarch 5, 2025 | finanznachrichten.deCumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comSee More Headlines CPIX Stock Analysis - Frequently Asked Questions How have CPIX shares performed this year? Cumberland Pharmaceuticals' stock was trading at $2.37 on January 1st, 2025. Since then, CPIX shares have increased by 105.5% and is now trading at $4.87. View the best growth stocks for 2025 here. How were Cumberland Pharmaceuticals' earnings last quarter? Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released its earnings results on Tuesday, March, 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The specialty pharmaceutical company earned $10.44 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative trailing twelve-month return on equity of 9.50%. Read the conference call transcript. Who are Cumberland Pharmaceuticals' major shareholders? Cumberland Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.52%). Insiders that own company stock include Kenneth Krogulski, James Jones and Caroline Young. View institutional ownership trends. How do I buy shares of Cumberland Pharmaceuticals? Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cumberland Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cumberland Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Exxon Mobil (XOM), Netflix (NFLX) and Intel (INTC). Company Calendar Last Earnings3/04/2025Today4/29/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CPIX CIK1087294 Webwww.cumberlandpharma.com Phone(615) 255-0068Fax615-255-0094Employees80Year Founded1999Profitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,280,000.00 Net Margins-29.54% Pretax Margin-29.32% Return on Equity-9.50% Return on Assets-3.19% Debt Debt-to-Equity Ratio0.41 Current Ratio1.13 Quick Ratio0.99 Sales & Book Value Annual Sales$37.87 million Price / Sales1.81 Cash Flow$0.57 per share Price / Cash Flow8.61 Book Value$1.96 per share Price / Book2.50Miscellaneous Outstanding Shares13,968,000Free Float7,962,000Market Cap$68.44 million OptionableOptionable Beta-0.24 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CPIX) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cumberland Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.